NCT05944510View on ClinicalTrials.gov

Dextromethorphan as an Augmentation Agent in Treatment-resistant Schizophrenia

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 31, 2023

Primary Completion Date

October 15, 2024

Study Completion Date

April 30, 2025

Conditions
Treatment Resistant Schizophrenia
Interventions
DRUG

Dextromethorphan

Dextromethorphan 30mg will be administered along with Clozapine (standard of care) in treatment resistant schizophrenia.

DRUG

Placebo

Matched placebo will be administered along with Clozapine (standard of care) in treatment resistant schizophrenia.

Trial Locations (1)

751019

All India Institute of Medical Sciences (AIIMS), Bhubaneswar

All Listed Sponsors
lead

All India Institute of Medical Sciences, Bhubaneswar

OTHER

NCT05944510 - Dextromethorphan as an Augmentation Agent in Treatment-resistant Schizophrenia | Biotech Hunter | Biotech Hunter